AZN AstraZeneca PLC

By Carlo Martuscelli

AstraZeneca PLC (AZN.LN) reported mixed results from a phase 3 clinical trial for its drug Farxiga, a treatment for cardiovascular disease in patients with diabetes.

The pharmaceutical major said on Monday that Farxiga didn't meet its efficacy objective of reducing major adverse cardiovascular events in a statistically significant way.

However the treatment was effective in reducing hospitalization for heart failure and cardiovascular death, the drug maker said.

AstraZeneca said it will present detailed results from the trial, called Declare, on Nov. 10.

Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com

(END) Dow Jones Newswires

September 24, 2018 02:29 ET (06:29 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.